Wall Street expects a year-over-year decline in earnings on lower revenues when Arcturus Therapeutics (ARCT) reports results for the quarter ended March 2024. While this widely-known consensus outlook...
Source LinkWall Street expects a year-over-year decline in earnings on lower revenues when Arcturus Therapeutics (ARCT) reports results for the quarter ended March 2024. While this widely-known consensus outlook...
Source Link
Comments